195 related articles for article (PubMed ID: 20880342)
1. Potential therapeutic uses for ezetimibe beyond lowering LDL-c to decrease cardiovascular events.
Ahmed MH; Byrne CD
Diabetes Obes Metab; 2010 Nov; 12(11):958-66. PubMed ID: 20880342
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393
[TBL] [Abstract][Full Text] [Related]
3. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
Ahmed MH; Byrne CD
Drug Discov Today; 2010 Aug; 15(15-16):590-5. PubMed ID: 20601094
[TBL] [Abstract][Full Text] [Related]
4. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
5. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
6. The role of ezetimibe in the prevention of cardiovascular disease: where do we stand after ARBITER 6-HALTS.
Howard WJ
Nutr Metab Cardiovasc Dis; 2010 Jun; 20(5):295-300. PubMed ID: 20556890
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease.
Abel T; Fehér J; Dinya E; Eldin MG; Kovács A
Med Sci Monit; 2009 Dec; 15(12):MS6-11. PubMed ID: 19946244
[TBL] [Abstract][Full Text] [Related]
8. [An inhibitor of intestinal cholesterol transporter].
Sano M
Nihon Rinsho; 2013 Sep; 71(9):1661-6. PubMed ID: 24205731
[TBL] [Abstract][Full Text] [Related]
9. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
10. Ezetimibe: cholesterol lowering and beyond.
Bays HE; Neff D; Tomassini JE; Tershakovec AM
Expert Rev Cardiovasc Ther; 2008 Apr; 6(4):447-70. PubMed ID: 18402536
[TBL] [Abstract][Full Text] [Related]
11. Ezetimibe as a potential treatment for dyslipidemia associated with chronic renal failure and renal transplant.
Ahmed MH; Khalil AA
Saudi J Kidney Dis Transpl; 2010 Nov; 21(6):1021-9. PubMed ID: 21060168
[TBL] [Abstract][Full Text] [Related]
12. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
Ballantyne CM; Abate N; Yuan Z; King TR; Palmisano J
Am Heart J; 2005 Mar; 149(3):464-73. PubMed ID: 15864235
[TBL] [Abstract][Full Text] [Related]
13. Ezetimibe in hypercholesterolaemia.
Farnier M
Int J Clin Pract; 2002 Oct; 56(8):611-4. PubMed ID: 12425372
[TBL] [Abstract][Full Text] [Related]
14. Co-administration of ezetimibe and simvastatin in acute myocardial infarction.
Chenot F; Montant PF; Marcovitch O; Blaimont M; de Meester A; Descamps OS
Eur J Clin Invest; 2007 May; 37(5):357-63. PubMed ID: 17461981
[TBL] [Abstract][Full Text] [Related]
15. Ezetimibe and recent clinical trials: a look on the bright side.
Ahmed MH
Expert Opin Drug Saf; 2010 Jul; 9(4):511-4. PubMed ID: 20377476
[TBL] [Abstract][Full Text] [Related]
16. Ezetimibe in diabetes: more than cholesterol lowering?
Sarigianni M; Katsiki N; Mikhailidis DP
Curr Med Res Opin; 2010 Oct; 26(10):2517-20. PubMed ID: 20843163
[TBL] [Abstract][Full Text] [Related]
17. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels.
Pearson T; Ballantyne C; Sisk C; Shah A; Veltri E; Maccubbin D
Am J Cardiol; 2007 Jun; 99(12):1706-1713. PubMed ID: 17560879
[TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of ezetimibe-based therapy in patients with dyslipidemia.
Miura S; Saku K
J Cardiol; 2008 Aug; 52(1):1-6. PubMed ID: 18639771
[TBL] [Abstract][Full Text] [Related]
19. Effects of ezetimibe on atherosclerosis in preclinical models.
Davis HR; Lowe RS; Neff DR
Atherosclerosis; 2011 Apr; 215(2):266-78. PubMed ID: 21397230
[TBL] [Abstract][Full Text] [Related]
20. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins.
Geiss HC; Otto C; Parhofer KG
Metabolism; 2006 May; 55(5):599-604. PubMed ID: 16631435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
